Bristol Myers beats quarterly profit estimates in its latest earnings report, driven by strong demand for its blood thinner and newer cancer treatments. The company posted adjusted earnings of USD 1.58 per share, topping analyst expectations...
The National Health Summit concluded today with a strong focus on Evidence-Based Health Reforms guided by findings from the 17th Common Review Mission (CRM) under the National Health Mission. The second day centered on technical discussions...
The Top Stories shaping the Pharma Industry right now show a clear shift—global deals, AI-led innovation, and policy clarity are driving momentum. From major acquisitions to breakthrough trials and public health moves, these updates reflect...
Zydus Lifesciences has expanded its presence in France healthcare market with a €700,000 acquisition of FBC Medical, a move that strengthens its position in the medical equipment distribution sector. The deal marks another step in the compan...
The Delhi government is planning to strengthen homoeopathy services and bring AYUSH systems closer to mainstream healthcare as part of a broader effort to improve access to treatment across the city.
Jharkhand has cleared a major step toward modernizing its public health system with the adoption of AI in healthcare, alongside a collaboration with Google to strengthen its digital backbone. The move is aimed at improving diagnostics, managing...
As India’s healthcare sector undergoes rapid transformation driven by policy reforms, digital health initiatives, and increasing focus on quality and accessibility, the need for skilled professionals with strong managerial and leadership...
Aurigene Pharmaceutical Services is set to invest nearly $100 million investment to expand its CRDMO business, strengthening its role in the growing pharmaceutical outsourcing market.
Pfizer has reached agreements with several generic drug manufacturers that will allow its heart medicine Vyndamax to remain free from generic competition in the United States until 2031. The move gives the company more time to maintain stron...
Eli Lilly and Company is making a fresh move in blood cancer treatment with its plan to acquire Ajax Therapeutics for up to USD 2.3 billion. The deal shows how Eli Lilly is doubling down on blood cancer therapies as it looks to build a stronger...
.jpg)
, CDSCO.jpg)